Lab
American Health Network of Indiana, LLC
American Health Network of Indiana, LLC was paid $1.62M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 80050, General health panel — 25% of everything it billed.
33Billing provider infoAMERICAN HEALTH NETWORK OF INDIANA, LLC
CARMEL, IN 46032
CARMEL, IN 46032
33aNPI1770621161assigned 02/01/2007
33bProvider typeClinical Medical Laboratory
28Total paid$1.62M
24GClaims230,973
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Indiana
Rank by total paid#11 of 66
Median peer was paid$53K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,668 | $24K | |
| 2019 | 22,822 | $29K | |
| 2020 | 15,639 | $50K | |
| 2021 | 46,588 | $457K | |
| 2022 | 43,680 | $374K | |
| 2023 | 44,081 | $405K | |
| 2024incomplete | 31,495 | $281K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80050 | General health panel | 25% | 9,912 | 8,576 | $398K |
| 80061 | Lipid panel | 9.9% | 26,721 | 24,150 | $160K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.7% | 2,676 | 2,358 | $141K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7.8% | 9,156 | 8,278 | $127K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.4% | 5,178 | 4,442 | $120K |
| 83036 | Hemoglobin; glycosylated (A1C) | 5.8% | 21,741 | 19,730 | $94K |
| 80053 | Comprehensive metabolic panel | 5.1% | 25,290 | 23,103 | $83K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.5% | 13,847 | 12,724 | $57K |
| 82607 | 2.9% | 6,641 | 5,969 | $47K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 20,077 | 18,267 | $43K |
| 84439 | 2.1% | 7,393 | 6,664 | $34K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.9% | 1,160 | 979 | $31K |
76 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.6% | 694 | $25K |
| 84153 | 1.4% | 1,645 | $22K | |
| 82728 | 1.3% | 2,910 | $20K | |
| 82746 | 1.1% | 2,649 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 814 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,612 | $13K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,052 | $12K |
| 84481 | <1% | 962 | $11K | |
| 83550 | <1% | 2,663 | $11K | |
| 82043 | <1% | 4,609 | $11K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 380 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 380 | $11K |
| 83540 | <1% | 3,311 | $10K | |
| 82550 | <1% | 4,499 | $10K | |
| 82570 | <1% | 4,740 | $10K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 310 | $9K |
| 83970 | <1% | 472 | $7K | |
| 84403 | <1% | 315 | $5K | |
| 83735 | <1% | 1,934 | $5K | |
| 84550 | <1% | 2,220 | $4K | |
| 85027 | <1% | 870 | $4K | |
| 85652 | <1% | 2,443 | $4K | |
| 81001 | <1% | 2,782 | $3K | |
| 80076 | <1% | 1,182 | $3K | |
| 86803 | <1% | 271 | $3K | |
| 83690 | <1% | 604 | $2K | |
| 86592 | <1% | 682 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 262 | $2K |
| 86140 | <1% | 537 | $2K | |
| 80051 | <1% | 883 | $2K | |
| 86225 | <1% | 185 | $2K | |
| 86038 | <1% | 199 | $2K | |
| 83721 | <1% | 598 | $2K | |
| 82310 | <1% | 918 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 40 | $1K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 171 | $1K |
| 86430 | <1% | 240 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 880 | $931.85 |
| 83001 | <1% | 62 | $852.81 | |
| 82150 | <1% | 196 | $822.75 | |
| 80074 | <1% | 38 | $728.13 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 35 | $725.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17 | $718.34 |
| 83880 | <1% | 87 | $549.89 | |
| 83525 | <1% | 56 | $523.50 | |
| 83002 | <1% | 37 | $500.04 | |
| 82670 | <1% | 12 | $279.40 | |
| 86376 | <1% | 22 | $240.10 | |
| 82947 | <1% | 158 | $205.15 | |
| 82248 | <1% | 107 | $172.88 | |
| 84702 | <1% | 16 | $118.83 | |
| 84100 | <1% | 63 | $114.71 | |
| 87186 | <1% | 13 | $100.35 | |
| 84460 | <1% | 62 | $96.32 | |
| 83615 | <1% | 48 | $67.78 | |
| 84450 | <1% | 33 | $63.35 | |
| 87340 | <1% | 14 | $60.38 | |
| 3044F | <1% | 2,598 | $60.00 | |
| 84156 | <1% | 32 | $44.77 | |
| 86850 | <1% | 15 | $14.98 | |
| 3049F | 0% | 222 | $0.00 | |
| 3080F | 0% | 513 | $0.00 | |
| 3074F | 0% | 3,089 | $0.00 | |
| 3075F | 0% | 936 | $0.00 | |
| 3048F | 0% | 593 | $0.00 | |
| 3008F | 0% | 7,967 | $0.00 | |
| 3061F | 0% | 569 | $0.00 | |
| 3079F | 0% | 2,788 | $0.00 | |
| 3060F | 0% | 49 | $0.00 | |
| 3046F | 0% | 281 | $0.00 | |
| 3078F | 0% | 4,276 | $0.00 | |
| 3077F | 0% | 873 | $0.00 | |
| 3050F | 0% | 126 | $0.00 | |
| 3062F | 0% | 16 | $0.00 | |
| 3045F | 0% | 230 | $0.00 | |
| 3051F | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBENSON, MARK (CHIEF PHYSICIAN EXECUTIVE)
Parent organizationAMERICAN HEALTH NETWORK OF INDIANA, LLC
| Provider | Location | Paid |
|---|---|---|
| Radiology Associates, INC | Wheeling, WV | $6.81M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.